UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience

PloS one, 2022-08, Vol.17 (8), p.e0264800-e0264800

2022

Volltextzugriff (PDF)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date

OncoTargets and therapy, 2018-01, Vol.11, p.2141-2147

2018

Volltextzugriff (PDF)

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2023-04, Vol.28 (4), p.366-e224

2023

Volltextzugriff (PDF)

Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer

Nature reviews. Clinical oncology, 2017-05, Vol.14 (5), p.269-283

2017

Volltextzugriff (PDF)

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.147-147

2024

Volltextzugriff (PDF)

Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.118-118

2023

Volltextzugriff (PDF)

Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.117-117

2023

Volltextzugriff (PDF)

Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.135-135

2023

Volltextzugriff (PDF)

Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?

Nature reviews. Clinical oncology, 2015-06, Vol.12 (6), p.316-318

2015

Volltextzugriff (PDF)

Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.112-112

2022

Volltextzugriff (PDF)

Is docetaxel the 'black widow' of mCRPC drugs?

Nature reviews. Clinical oncology, 2015-06, Vol.12 (6), p.316-318

2015

Volltextzugriff (PDF)

Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.467-467

2019

Volltextzugriff (PDF)

Evolving patterns of metastatic renal cell carcinoma: A meta-analysis

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.563-563

2019

Volltextzugriff (PDF)

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17575-e17575

2020

Volltextzugriff (PDF)

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.89-89

2020

Volltextzugriff (PDF)

Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17027-e17027

2021

Volltextzugriff (PDF)

Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy

American journal of clinical oncology, 2024-06, Vol.47 (6), p.271-278

2024

Volltextzugriff (PDF)

MP27-10 CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING FOR PROSTATE CANCER IN THE CONTEXT OF A CHANGING TREATMENT LANDSCAPE

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.310-310

2019

Volltextzugriff (PDF)

Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.184-184

2019

Volltextzugriff (PDF)

Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.309-309

2019

Volltextzugriff (PDF)

Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17047-e17047

2021

Volltextzugriff (PDF)

Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer

JCO clinical cancer informatics, 2022-06, Vol.6 (6), p.e2200010

2022

Volltextzugriff (PDF)

Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy

Current urology reports, 2015-03, Vol.16 (3), p.13-13, Article 13

2015

Volltextzugriff (PDF)

The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.41-41

2021

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(34)
Buchkapitel
(1)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(11)
Oncology
(10)
Prostate Cancer
(9)
Humans
(7)
Male
(7)
Antineoplastic Agents - Therapeutic Use
(4)
Androgen Antagonists - Therapeutic Use
(3)
Medicine & Public Health
(3)
Metastasis
(3)
Prostatic Neoplasms - Drug Therapy
(3)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(3)
692/699/67/589/466
(2)
692/700/565/1436/1437
(2)
Aged
(2)
Androgens
(2)
Cancer Therapies
(2)
Care And Treatment
(2)
Diagnosis
(2)
Docetaxel
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer

Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC

Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy

Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies

Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART)

Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?

Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape

Is docetaxel the 'black widow' of mCRPC drugs?

Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC)

Evolving patterns of metastatic renal cell carcinoma: A meta-analysis

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy

Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints

Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy

MP27-10 CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING FOR PROSTATE CANCER IN THE CONTEXT OF A CHANGING TREATMENT LANDSCAPE

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy

Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer

Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis

Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction

Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer

Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy

The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer

Suchergebnisse filtern